Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

38.06
+0.18000.48%
Post-market: 38.060.00000.00%19:30 EDT
Volume:114.36K
Turnover:4.36M
Market Cap:251.20M
PE:- -
High:38.28
Open:38.22
Low:38.01
Close:37.88
52wk High:41.49
52wk Low:22.33
Shares:6.60M
Float Shares:6.60M
Volume Ratio:0.62
T/O Rate:1.73%
Dividend:0.28
Dividend Rate:0.74%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.

TIPRANKS
·
Aug 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
Aug 27

24H | Okta Soars 21%; Salesforce Jumps 13%; CrowdStrike Rallies 10%; NVIDIA Climbs 4.6%

US Overnight
·
Aug 27

Moderna Inc. Stock Falls 5.8%, Underperforms Peers

Dow Jones
·
Aug 27

US Closing Bell | Wall St drifts lower as Dow dips 0.2%, Lumentum jumps 6%

US Closing Bell
·
Aug 27

Vertex to Present at Wells Fargo Healthcare Investor Conference Fireside Chat

Reuters
·
Aug 27

Cboe data shows mixed options sentiment in Moderna with shares down 7.64%

TIPRANKS
·
Aug 27

Roche receives FDA approval for companion diagnostic tests for Ziihera

TIPRANKS
·
Aug 27

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
Aug 27

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

US Stocks-Wall St Awaits Nvidia's AI Verdict After Hot Inflation Data

Reuters
·
Aug 27

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26